Accelerated hypofractionated radiotherapy with 3 Gy per fraction for central/ultra-central lung tumors: toxicity to mediastinal organs

被引:0
|
作者
Ito, Kei [1 ,3 ]
Minakami, Shota [1 ]
Nakajima, Yujiro [1 ,2 ]
Karasawa, Katsuyuki [1 ]
机构
[1] Tokyo Metropolitan Canc & Infect Dis Ctr Komagome, Dept Radiol, Div Radiat Oncol, Tokyo, Japan
[2] Komazawa Univ, Dept Radiol Sci, Tokyo, Japan
[3] Tokyo MetropolitanCancer & Infect Dis Ctr Komagome, Dept Radiol, Div Radiat Oncol, 3-18-22 Honkomagome,Bunkyo Ku, Tokyo 1138677, Japan
关键词
Accelerated hypofractionated radiotherapy; lung neoplasms; mediastinal organs; ultra-central lung tumor; BODY RADIATION-THERAPY; CANCER; CARCINOMA; OUTCOMES; SURGERY;
D O I
10.1093/jjco/hyac181
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Accelerated hypofractionated radiotherapy with 3 Gy per fraction is routinely performed for central lung tumors in Japan. However, the tolerable doses to mediastinal organs at risk during this procedure are unclear. This study aimed to clarify the rate of toxicities and tolerable doses to mediastinal organs. Methods Patients treated with accelerated hypofractionated radiotherapy using a total dose of 60-75 Gy, with 3 Gy per fraction, for central lung tumors (July 2009-April 2021) were retrospectively reviewed. We extracted patients who received >= 30 Gy irradiation to each mediastinal organ and analyzed dosimetric factors, including doses to 0.03, 0.5, 1, 4 and 10 mL of each organ, in relation to grade 3-5 toxicities, except for radiation pneumonitis. Results In total, 251 organs in 91 (ultra-central, 24) lesions were analyzed, with a median follow-up duration of 26 months (range, 4-94). The prescribed doses were 75/72/69/66/63/60 Gy for 52/14/16/3/2/4 lesions, respectively. Grade 3 bronchopulmonary hemorrhage was confirmed in two (2.2%) patients, whose tumors were located ultra-centrally. The two patients with toxicity received up to 74.5 and 71.6 Gy to the bronchus. Among patients who received 70 Gy or more to the bronchus, the incidence rate was 7% (2/28 patients). Conclusion The rate of severe toxicities was low (2.2%). Although we did not identify the dose tolerance of the organs, because of the low incidence rate, we did note that doses of >70 Gy to the bronchus were likely to cause bronchopulmonary hemorrhage. We evaluated the toxicity of accelerated hypofractionated radiotherapy for central lung tumors. The rate of severe toxicities was low (2.2%). The recommended threshold is 70 Gy to avoid bronchopulmonary hemorrhage.
引用
收藏
页码:237 / 244
页数:8
相关论文
共 50 条
  • [1] Lung Accelerated Hypofractionated Radiotherapy for Central Tumors
    Karasawa, K.
    Machitori, Y.
    Hayakawa, S.
    Shibata, Y.
    Ito, K.
    Shimizuguchi, T.
    Fujisawa, T.
    Miyake, Y.
    Ogawa, H.
    Nihei, K.
    Kito, S.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E512 - E512
  • [2] Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors
    Chaudhuri, Aadel A.
    Tang, Chad
    Binkley, Michael S.
    Jin, Michelle
    Wynne, Jacob F.
    von Eyben, Rie
    Hara, Wendy Y.
    Trakul, Nicholas
    Loo, Billy W., Jr.
    Diehn, Maximilian
    [J]. LUNG CANCER, 2015, 89 (01) : 50 - 56
  • [3] Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?
    Murrell, Donna H.
    Laba, Joanna M.
    Erickson, Abigail
    Millman, Barbara
    Palma, David A.
    Louie, Alexander V.
    [J]. RADIATION ONCOLOGY, 2018, 13
  • [4] Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?
    Donna H. Murrell
    Joanna M. Laba
    Abigail Erickson
    Barbara Millman
    David A. Palma
    Alexander V. Louie
    [J]. Radiation Oncology, 13
  • [5] Ten Fraction Ultra-Central Thoracic Hypofractionated Stereotactic Body Radiotherapy (hfSBRT): An Analysis of Outcomes, Dosimetry, and Toxicity
    Rock, C. D.
    Sood, S. S.
    Wang, F.
    Cao, Y.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E424 - E424
  • [6] Toxicity and Local Control in "Ultra-Central" Lung Tumors Treated With SBRT or High-Dose Hypofractionated RT
    Wang, C.
    Sidiqi, B.
    Yorke, E.
    Mcknight, D.
    Dick-Godfrey, R.
    Torres, D.
    Gelblum, D.
    Rimner, A.
    Wu, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S357 - S357
  • [7] Ultra-central lung tumors: safety and efficacy of protracted stereotactic body radiotherapy
    Lodeweges, Joyce E.
    van Rossum, Peter S. N.
    Bartels, Marcia M. T. J.
    van Lindert, Anne S. R.
    Pomp, Jacqueline
    Peters, Max
    Verhoeff, Joost J. C.
    [J]. ACTA ONCOLOGICA, 2021, 60 (08) : 1061 - 1068
  • [8] Ultra-central lung tumors: safety and efficacy of protracted stereotactic body radiotherapy
    Lodeweges, J.
    van Rossum, P.
    Bartels, M.
    van Lindert, A.
    Pomp, J.
    Peters, M.
    Verhoeff, J.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S972 - S973
  • [9] Toxicity of Patients with Ultra-Central Thoracic Tumors Treated with Stereotactic Body Radiotherapy (SBRT) with Dose of 50 Gy in 5 Fractions
    Asso, R. N.
    Kopek, N.
    Duclos, M.
    Abdulkarim, B. S.
    Connel, T.
    Ramia, P.
    Saidi, A.
    Faria, S. L.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E4 - E4
  • [10] Effect of Contralateral Esophagus Sparing in Hypofractionated Radiotherapy for Ultra-Central NSCLC
    Zhu, L. L.
    Khandekar, M. J.
    Choi, J.
    Bowes, C.
    Willers, H.
    Keane, F. K.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E82 - E82